

# Mertk Cas9-CKO Strategy

Designer:Xueting Zhang

# **Project Overview**



**Project Name** 

Mertk

**Project type** 

Cas9-CKO


Strain background

C57BL/6JGpt

# Conditional Knockout strategy



This model will use CRISPR/Cas9 technology to edit the Mertk gene. The schematic diagram is as follows:



### Technical routes



- The *Mertk* gene has 2 transcripts. According to the structure of *Mertk* gene, exon2 of *Mertk-201*(ENSMUST00000014505.4) transcript is recommended as the knockout region. The region contains 409bp coding sequence.

  Knock out the region will result in disruption of protein function.
- In this project we use CRISPR/Cas9 technology to modify *Mertk* gene. The brief process is as follows:CRISPR/Cas9 system and Donor were microinjected into the fertilized eggs of C57BL/6JGpt mice. Fertilized eggs were transplanted to obtain positive F0 mice which were confirmed by PCR and sequencing. A stable F1 generation mouse model was obtained by mating positive F0 generation mice with C57BL/6JGpt mice.
- The flox mice will be knocked out after mating with mice expressing Cre recombinase, resulting in the loss of function of the target gene in specific tissues and cell types.

### **Notice**



- According to the existing MGI data, Homozygotes for targeted null mutations show increased sensitivity to
   LPS-induced shock, defective phagocytosis of apoptotic cells, lupus-like autoimmunity, degeneration of
   photoreceptors, decreased platelet aggregation and protection from induced pulmonary thromboembolism and thrombosis.
- ➤ Transcript *Mertk*-202 may not be affected.
- The *Mertk* gene is located on the Chr2. If the knockout mice are crossed with other mice strains to obtain double gene positive homozygous mouse offspring, please avoid the two genes on the same chromosome.
- > This Strategy is designed based on genetic information in existing databases. Due to the complexity of biological processes, all risk of loxp insertion on gene transcription, RNA splicing and protein translation cannot be predicted at existing technological level.

## Gene information (NCBI)



#### Mertk MER proto-oncogene tyrosine kinase [Mus musculus (house mouse)]

Gene ID: 17289, updated on 30-Mar-2019

#### Summary

☆ ?

Official Symbol Mertk provided by MGI

Official Full Name MER proto-oncogene tyrosine kinase provided byMGI

Primary source MGI:MGI:96965

See related Ensembl:ENSMUSG00000014361

Gene type protein coding
RefSeq status VALIDATED
Organism Mus musculus

Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha;

Muroidea; Muridae; Murinae; Mus; Mus

Also known as Eyk, Mer, Nyk, nmf12

Expression Ubiquitous expression in lung adult (RPKM 4.8), kidney adult (RPKM 4.4) and 28 other tissuesSee more

Orthologs <u>human</u> all


# Transcript information (Ensembl)



The gene has 2 transcripts, all transcripts are shown below:


| Name      | Transcript ID        | bp   | Protein      | Biotype              | CCDS      | UniProt | Flags                         |
|-----------|----------------------|------|--------------|----------------------|-----------|---------|-------------------------------|
| Mertk-201 | ENSMUST00000014505.4 | 4302 | <u>994aa</u> | Protein coding       | CCDS16716 | Q60805  | TSL:1 GENCODE basic APPRIS P1 |
| Mertk-202 | ENSMUST00000140221.1 | 2744 | No protein   | Processed transcript | +8        | -       | TSL:1                         |

The strategy is based on the design of Mertk-201 transcript, The transcription is shown below




### Genomic location distribution






### Protein domain





# Mouse phenotype description(MGI)





Phenotypes affected by the gene are marked in blue.Data quoted from MGI database(http://www.informatics.jax.org/).

According to the existing MGI data, Homozygotes for targeted null mutations show increased sensitivity to LPS-induced shock, defective phagocytosis of apoptotic cells, lupus-like autoimmunity, degeneration of photoreceptors, decreased platelet aggregation and protection from induced pulmonary thromboembolism and thrombosis.



If you have any questions, you are welcome to inquire. Tel: 400-9660890





